Format

Send to

Choose Destination
See comment in PubMed Commons below
PLoS One. 2013 Dec 11;8(12):e81302. doi: 10.1371/journal.pone.0081302. eCollection 2013.

Phase 2a study of ataluren-mediated dystrophin production in patients with nonsense mutation Duchenne muscular dystrophy.

Author information

1
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States of America ; Nemours Children's Hospital, Orlando, Florida, United States of America.
2
University of Utah School of Medicine, Salt Lake City, Utah, United States of America.
3
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States of America.
4
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States of America.
5
Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, United States of America.
6
PTC Therapeutics, Inc., South Plainfield, New Jersey, United States of America.

Abstract

BACKGROUND:

Approximately 13% of boys with Duchenne muscular dystrophy (DMD) have a nonsense mutation in the dystrophin gene, resulting in a premature stop codon in the corresponding mRNA and failure to generate a functional protein. Ataluren (PTC124) enables ribosomal readthrough of premature stop codons, leading to production of full-length, functional proteins.

METHODS:

This Phase 2a open-label, sequential dose-ranging trial recruited 38 boys with nonsense mutation DMD. The first cohort (n = 6) received ataluren three times per day at morning, midday, and evening doses of 4, 4, and 8 mg/kg; the second cohort (n = 20) was dosed at 10, 10, 20 mg/kg; and the third cohort (n = 12) was dosed at 20, 20, 40 mg/kg. Treatment duration was 28 days. Change in full-length dystrophin expression, as assessed by immunostaining in pre- and post-treatment muscle biopsy specimens, was the primary endpoint.

FINDINGS:

Twenty three of 38 (61%) subjects demonstrated increases in post-treatment dystrophin expression in a quantitative analysis assessing the ratio of dystrophin/spectrin. A qualitative analysis also showed positive changes in dystrophin expression. Expression was not associated with nonsense mutation type or exon location. Ataluren trough plasma concentrations active in the mdx mouse model were consistently achieved at the mid- and high- dose levels in participants. Ataluren was generally well tolerated.

INTERPRETATION:

Ataluren showed activity and safety in this short-term study, supporting evaluation of ataluren 10, 10, 20 mg/kg and 20, 20, 40 mg/kg in a Phase 2b, double-blind, long-term study in nonsense mutation DMD.

TRIAL REGISTRATION:

ClinicalTrials.gov NCT00264888.

PMID:
24349052
PMCID:
PMC3859499
DOI:
10.1371/journal.pone.0081302
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Public Library of Science Icon for PubMed Central
    Loading ...
    Support Center